AngioDynamics Q3 Revenue Rises 8.9% to $78.4M, EPS Misses Estimates
AngioDynamics reported $78.4 million in fiscal Q3 net sales, up 8.9% year-over-year, surpassing the $76.8 million consensus. The company posted a GAAP net loss of $8.1 million (-$0.19/share), generated $1.8 million in adjusted EBITDA and raised full-year fiscal 2026 guidance for the third consecutive quarter.
1. Fiscal Q3 2026 Results
AngioDynamics recorded net sales of $78.4 million in its fiscal third quarter ended February 28, up 8.9% year-over-year and exceeding the $76.8 million consensus. GAAP net loss was $8.1 million ($0.19 per share), while adjusted EBITDA reached $1.8 million and adjusted loss per share was $0.07.
2. Segment Breakdown
The Medical Technology segment delivered net sales of $37.3 million, a 19% increase driven by strong demand for Auryon, AlphaVac and NanoKnife platforms. The Medical Device segment contributed $41.1 million in sales, up 1.1% year-over-year.
3. Financial Position and Outlook
AngioDynamics ended the quarter with $37.8 million in cash and zero debt, using approximately $3.0–3.1 million in cash during the period. Management raised full-year fiscal 2026 guidance for the third consecutive quarter, citing continued momentum in the high-margin Medical Technology portfolio.